Trial site
Allgemeines Krankenhaus Der Stadt Wien Universitatskliniken
- 9running trials
- 14closed trials
The trials here
What the 23 trials at this site are about, from their registry records.
- Conditions
- High blood pressure3 trials
- Liver cirrhosis3 trials
- Hidradenitis suppurativa2 trials
- Atopic dermatitis (eczema)1 trial
- Chronic kidney disease1 trial
- Crohn's disease1 trial
- Dermatomyositis and polymyositis (myositis)1 trial
- Diffuse large B-cell lymphoma1 trial
- Fatty liver disease (MASLD/MASH)1 trial
- Follicular lymphoma1 trial
- Haemophilia1 trial
- Hodgkin lymphoma1 trial
- and 10 more
- Phase
- Phase 317 trials
- Phase 43 trials
- Phase 22 trials
- Phase 2/31 trial
- Status
- Completed14 trials
- Active, not recruiting6 trials
- Not yet recruiting2 trials
- Recruiting1 trial
- Lead sponsor
- Boehringer Ingelheim4 trials
- Eli Lilly and Company4 trials
- AstraZeneca3 trials
- Novartis Pharmaceuticals2 trials
- Acceleron Pharma Inc.1 trial
- and 9 more
Running trials
Recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
Enrolling by invitation
Recruiting
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Active, not recruiting
Active, not recruiting
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
Active, not recruiting
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Fatty liver disease (MASLD/MASH)1 recruiting
- Liver cirrhosis1 recruiting
- Prostate cancer1 recruiting
- Sjögren's disease1 recruiting
Closed trials
Terminated
Completed
Completed
Completed
Completed
Terminated
Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
Completed
A Long-term Follow-up Study of Sotatercept for PAH Treatment
Completed
Completed
Completed
Active, not recruiting
Completed
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
Completed
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
Completed
Site data: EU CTIS (euclinicaltrials.eu)Updated 17 Nov 2026